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Since the discovery of the endomorphins (EM), the postulated endogenous peptide agonists of the mu-opioid receptors, several
analogues have been synthesized to improve their binding and pharmacological profiles. We have shown previously that a
new analogue, cis-1S,2R-aminocyclohexanecarboxylic acid2-endomorphin-2 (ACHC-EM2), had elevated mu-receptor affinity,
selectivity, and proteolytic stability over the parent compound. In the present work, we have studied its antinociceptive effects
and receptor regulatory processes. ACHC-EM2 displayed a somewhat higher (60%) acute antinociceptive response than the parent
peptide, EM2 (45%), which peaked at 10min after intracerebroventricular (icv) administration in the rat tail-flick test. Analgesic
tolerance developed to the antinociceptive effect of ACHC-EM2 upon its repeated icv injection that was complete by a 10-day
treatment. This was accompanied by attenuated coupling of mu-sites to G-proteins in subcellular fractions of rat brain. Also, the
density of mu-receptors was upregulated by about 40% in the light membrane fraction, with no detectable changes in surface
binding. Distinct receptor regulatory processes were noted in subcellular fractions of rat brains made tolerant by the prototypic full
mu-agonist peptide, DAMGO, and its chloromethyl ketone derivative, DAMCK.These results are discussed in light of the recently
discovered phenomenon, that is, the “so-called biased agonism” or “functional selectivity”.
1. Introduction
Recently discovered endomorphin-1 (Tyr-Pro-Trp-Phe-NH
2,
EM1) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH
2
, EM2),
which display high affinity and selectivity to mu-opioid
receptors, proved to be effective against neuropathic and
inflammatory pain with reduced side effects [1, 2]. Besides
their essential pharmacophoric groups (Tyr1, Phe3, and the
amidated C-terminus), they have a proline in the second
position that serves as a stereochemical spacer. Substitution
of Pro2 by alicyclic beta-amino acids has been shown to cause
profound changes in bioactive conformation, proteolytic sta-
bility, and pharmacological activity [3]. Endomorphin-2 con-
taining cis-(1R,2S)-ACPC2 residue (ACHC-EM2) displayed
higher binding affinity, improved mu-receptor selectivity,
and enhanced proteolytic stability compared to the parent
peptide [3, 4]. These features make it a promising tool to
study the conformational requirements of peptide binding to
mu-receptor.
Opioids are among the most commonly used analgesics,
but their clinical use is limited by the development of various
unwanted side effects such as tolerance, physical dependence,
and respiratory suppression. It has become apparent that
analgesic tolerance and dependence are very complex phe-
nomena, which involve changes at the cellular, neuronal, and
system levels [5–9]. Traditionally, receptor desensitization
(uncoupling the receptor and G-protein), internalization
(trafficking the cell surface receptors into an intracellular
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compartment), and/or downregulation (decrease in the total
number of receptors) have been proposed as possible mech-
anisms for tolerance [6–15]. Importantly, while endogenous
opioid peptides efficiently desensitized and internalized mu-
opioid receptors, the highly addictive morphine failed to
inducemeasurable changes [11–18].There are conflicting data
whether there is a linear relationship between the intrinsic
efficacy of a ligand and its ability to promote receptor interna-
lization [19–22]. Whistler and colleagues have suggested that
receptor endocytosis plays a protective role in reducing the
development of tolerance [8, 15, 23]. Another new hypothesis
is that opioid tolerance may also result from amplification or
induction of an opioid receptor-coupled signal transduction
pathway that is either poorly expressed or absent from opioid
naive tissue [24]. Very recently, it has been revealed that
the mu-opioid receptors, besides other G-protein coupled
receptors, display “functional agonism,” also called “agonist-
directed trafficking” or “biased agonism” implying that differ-
ent agonists, while acting at the same receptor site, can induce
distinct molecular changes and activate distinct downstream
responses [25, 26].
Most works on opioid receptor trafficking were carried
out in various in vitro cell models. The limitations of these
models are obvious, including differences in cellular milieu
and receptor expression levels. The study of endogenous
opioid receptors using in vivo models has produced some
interesting results that could not have been anticipated in
vitro [27]. As part of a comprehensive work using various
mu-opioid ligands of distinct efficacy, chemical nature, and
abuse potential, we attempt to correlate receptor regulatory
changes with analgesic tolerance. It has been shown that
sustained morphine treatment of rats, leading to analgesic
tolerance, did not change the density or G-protein coupling
of the surface mu-opioid receptors. However, significant
intracellular changes, including upregulation of the mu-
sites and their cognate G-proteins, were noted in the light
membrane fraction [28]. In addition, we have described that
14-methoxymetopon, an extremely potent, centrally acting
mu-opioid specific analgesic with low tolerance, physical
dependence, and other side effects, when given to rats either
acutely or chronically, did not change the binding or G-
protein signaling of mu-opioid receptors in rat brain subcel-
lular membranes [29]. We have hypothesized that whereas
surface opioid receptors and their cognate G-proteins medi-
ate the acute effect of opioids, intracellular events may play a
crucial role in the long-term changes elicited by chronic drug
exposure [28].
In the present work, we have examined the new endo-
morphin analogue, ACHC-EM2, for its antinociceptive
effect and receptor regulatory changes after acute and
prolonged in vivo treatments. The model system used
is based on subcellular fractionation of rat brains fol-
lowed by ligand binding and functional measurements.
Detailed characterization of the subcellular fractions by
marker enzymes, electron microscopy, and receptor bind-
ing experiments has been reported [28–31]. To assess
changes in the intracellular distribution of mu-opioid recep-
tors, subcellular fractionation was combined with radioli-
gand binding measurements. The degree of desensitization
was estimated by ligand-stimulated guanosine-5󸀠-O-(3-[𝛾
[35S]hio)triphosphate, [35S]GTP𝛾S functional assays. It is
concluded that the regulatory changes accompanyingACHC-
EM2 analgesic tolerance are distinct from those of the
prototypic mu-agonist peptide, DAMGO (Tyr-D-Ala-Gly-
(NMe)Phe-Gly-ol), and its chloromethyl derivative, DAMCK
(Tyr-D-Ala-Gly-(NMe)Phe-CH
2
Cl).
2. Materials and Methods
2.1. Chemicals. Endomorphin derivatives were synthesized
as published [3]. DAMGO and [3H]DAMGO (36 Ci/mmol)
were prepared and kindly provided to us by Drs. Farkas
and To´th (Biological Research Center, Szeged, Hungary)
or purchased from Multiple Peptide System (San Diego,
CA, USA). DAMCK was synthesized as published [32] by
Anna Magyar (ELTE, Budapest, Hungary). [35S]GTP𝛾S was
obtained from Isotope Institute Ltd. (Budapest, Hungary).
Tris(hydroxymethyl)aminomethane, (Tris, free base),
sodium chloride (NaCl), ethylenebis(oxyethylenenitrilo)
tetraacetic acid (EGTA), guanosine 5󸀠-diphosphate sodium
salt (GDP), guanosine 5󸀠-triphosphate sodium salt (GTP),
guanosine 5󸀠-[𝛾-thio]triphosphate tetralithium salt (GTP-𝛾-
S-Li
4
), magnesium chloride hexahydrate (MgCl
2
× 6H
2
O),
dithiothreitol, sucrose, and Nembutal were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Bradford reagent was
from Bio-Rad Laboratories (Hercules, CA, USA).
2.2. Animals. Wistar rats (250–500 g) were used. They were
kept under a standard light-dark cycle with food and water
available ad libitum. The animals were kept and treated
according to the rules of the Ethical Committee for the
Protection of Animals in Research (University of Szeged and
Biological ResearchCenter of theHungarianAcademy of Sci-
ences, Szeged, Hungary). All efforts were made to minimize
their suffering during treatments.The animalswere randomly
assigned to treatment groups (𝑛 = 4/dose/treatment).
2.3. Surgery. For intracerebroventricular (icv) peptide admin-
istration, the rats were implanted with a stainless steel
Luer cannula (10mm long) aimed at the right lateral cere-
bral ventricle under Nembutal (35mg/kg, intraperitoneally)
anesthesia [32]. The stereotaxic coordinates were 0.2mm
posterior, 1.7mm lateral to the bregma, and 3.7mm deep
from the dural surface, according to the atlas of Pellegrino
et al. [33]. Cannulas were secured to the skull with dental
cement and acrylate. The experiments were started 5 days
after icv cannulation. All icv treatments were delivered to
freely moving animals to prevent unspecific effects. Upon
conclusion of the experiments, 10 𝜇L of methylene blue was
injected into the ventricle of decapitated animals and the
position of the cannula was inspected visually. Animals with
improper cannula placement were excluded from the final
statistical analysis.
2.4. In Vivo Opioid Treatments. The peptides were dissolved
in artificial cerebrospinal fluid (CSF) and injected in a volume
of 2 𝜇L. Endomorphins were administered either acutely at
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the indicated doses (100 pg–20𝜇g) or chronically at 20𝜇g for
10 days (twice daily) and tested at the indicated times. Vehicle
control groups obtaining CSF were used in all experiments,
and no changes were detected in the antinociceptive response
of the control group. DAMGO and DAMCK were injected
at 10 𝜇g twice daily for 8 days. Animals were killed 16 hrs
after drug treatments by decapitation immediately followed
by subcellular fractionation.
2.5. Tail-Flick (TF) Antinociceptive Assay. The original
method of D’Amour was used to determine analgesia in the
rat by measuring the time required to respond to a radiating
heat stimulus [32]. A beam light was focused on the tip of the
tail, and the latency required for the rat to remove its tail was
determined before (baseline) and after drug administration.
The animals were tested at the times shown after injection
of the peptides. The antinociceptive effect was expressed
according to the equation: (TF
𝑛
− TF
𝑜
) × 100/TFmax − TF𝑜,
where TF
𝑜
is the tail-flick latency before drug administration,
TF
𝑛
is the value of a repeated corresponding measurement
after drug injection, and TFmax indicates the cutoff time
which was set at 10 sec in our assays. Statistical analysis of the
data of tail-flick antinociceptive test was made by ANOVA.
For significant ANOVA values, groups were compared by
Tukey’s test for multiple comparisons with unequal cell size.
A probability level, 𝑃 < 0.05, was accepted to label significant
differences.
2.6. Crude Rat Brain Membranes. Crude brain membranes
were prepared as published [34]. Briefly, pooled brain tissues
without cerebella of four rats were washed with ice-cold
buffer and their weight was measured. They were homoge-
nized in 30 volumes (v/w) of ice-cold 50mMTris-HCl buffer
(pH 7.4). Homogenates were centrifuged at 20,000×g for
25min, and the resulting pellets suspended in buffer and
spun again. Pellets were taken up in the original volume
of buffer and incubated for 30min at 37∘C, followed by
centrifugation at 20,000×g for 25min. The supernatants
were carefully discarded, and the final pellets were taken
up in 5 volumes (v/w) of 50mM Tris-HCl buffer (pH 7.4)
containing 0.32M sucrose. Appropriate membrane aliquots
were stored at −80∘C for several weeks. Prior to the binding
experiments, an appropriate aliquot was thawed, diluted
with 5-fold Tris-HCl buffer, and centrifuged at 20,000×g for
25min to remove sucrose. The resulting pellets were taken
up in 50mM Tris-HCl buffer (pH 7.4) to yield in 0.3–0.5mg
membrane protein/mL.
2.7. Subcellular Fractionation of Rat Brains. Subcellular frac-
tions of rat brains were purified as published [28, 29]. Briefly,
fresh forebrains of four rats were pooled, gently homogenized
in 10 volumes (v/w) of ice-cold buffer (5mM Tris-HCl pH
7.4, 50 𝜇M CaCl
2
, 0.5mM dithiothreitol), and supplemented
with 10% sucrose. All sucrose solutions were made in the
above buffer. The homogenate was spun at 1,000×g for
10min. The resulting pellet was resuspended in the above
buffer and spun again. The combined supernatants were
spun at 12,000×g for 20min. The pellets were suspended in
10% sucrose and subjected to consecutive centrifugations at
20,000×g for 25min and 14,000×g for 20min twice resulting
in crude synaptic plasma membranes (SPM). The resulting
pellets were lysed followed by fractionation on a 10%, 28.5%,
and 34% sucrose density step gradient that was spun at
100,000×g for 2 h. Highly enriched SPMs were obtained
from the 28/34% interface. Crude microsomal (MI) fractions
were obtained from the 12,000×g supernatant by consecu-
tive centrifugations at 20,000×g for 25min and 100,000×g
for 1 h. MI fractions were purified on a 10% and 28.5%
sucrose step gradient centrifuged at 100,000×g for 2 h and
collected at 10/28.5% interface. SPM and MI fractions were
diluted threefold with 50mM Tris-HCl buffer and pelleted
at 100,000×g for 1 h to remove sucrose. The resulting pellets
were taken up in 50mM Tris-HCl (pH 7.4) buffer to yield in
0.3–0.8mg membrane protein/ml and were freshly used.
2.8. Protein Concentration. The protein content of the mem-
brane preparations was determined by the method of Brad-
ford using bovine serum albumin as a standard [35].
2.9. [3H]DAMGO Binding Assay. Briefly, homologous
displacement assays were performed by incubating
[3H]DAMGO (≈1 nM) with 11 concentrations of unlabeled
DAMGO (10−10–10−5M) and the membrane suspension
(200–300𝜇g protein) in 50mM Tris-HCl (pH 7.4) buffer
in a final volume of 1mL as described [28, 29]. The tubes
were incubated at 25∘C for 1 h. The reaction was stopped by
vacuum filtration through Whatman GF/C glass fiber filters
(Whatman, Maidstone, England) using a Brandel M24-R
Cell Harvester (Brandel, Gaithersburg, MD, USA). Filters
were rapidly washed with 3 × 5mL ice-cold 50mM Tris-HCl
(pH 7.4) buffer, air-dried, and counted in a toluene-based
scintillation cocktail in a Wallac 1409 scintillation counter
(Wallac, Turku, Finland). All experiments were performed
in duplicate and repeated at least three times. Curves were
constructed and analyzed by means of the GraphPad Prism
4 program (GraphPad Software, Inc., San Diego, CA, USA.)
to obtain 𝐾
𝐷
(dissociation constant) and 𝐵max (receptor
density) values. The data reported are means ± S.E.M.
2.10. Ligand-Stimulated [35S]GTP𝛾S Functional Assay. The
assay was performed as published [28, 29] with slight mod-
ifications. Briefly, rat brain membrane fractions (≈10 𝜇g of
protein) were incubated with [35S]GTP𝛾S (0.05 nM) and 5-
6 concentrations (10−9−10−4M) of opioid peptides in the
presence of 100𝜇M GDP in Tris-EGTA (50mM Tris-HCl,
1mM EGTA and 5mM MgCl
2
; pH 7.4) buffer in a total
volume of 1mL for 60min at 30∘C. Nonspecific binding was
determined with 10 𝜇M GTP𝛾S and subtracted. Bound and
free [35S]GTP𝛾S were separated by vacuumfiltration through
Whatman GF/F filters using a Brandel M24-R Cell Harvester
(Brandel, Gaithersburg, MD, USA). Filters were rapidly
washed with 3 × 5mL ice-cold 50mM Tris-HCl (pH 7.4)
buffer, air-dried, and counted in a toluene-based scintillation
cocktail in aWallac 1409 scintillation counter (Wallac, Turku,
Finland). All assays were performed in triplicate and repeated
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Figure 1: Time-course of the acute antinociceptive effect of graded doses of EM2 (a) and ACHC-EM2 (b) in rat tail-flick assay. The peptides
were administered icv and assayed as described in Methods. Control groups received CSF. Data are shown as mean ± S.E.M; 𝑛 ≥ 6. Statistical
significance was determined by ANOVA and set at ∗𝑃 < 0.05 compared to appropriate control values.
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Figure 2:Development of antinociceptive tolerance to chronicACHC-EM2given at 20𝜇g/2 𝜇L twice daily for the indicated time periods. Rats
were tested in the tail-flick assay 5min (a, white columns) and 15min (b, striped columns) after injection. Mean ± S.E.M.; 𝑛 = 7. Significance
was determined by ANOVA; ∗ labels 𝑃 < 0.05 compared to the first day.
at least three times. Curves were constructed and analyzed by
fitting sigmoidal dose-response curves using the GraphPad
Prism 4 program (GraphPad Prism Software Inc) to obtain
potency (EC
50
, concentration of the ligand to give half-
maximal effect) and efficacy (𝐸max, % maximal stimulation
over basal activity) values. Basal activities were measured in
the absence of opioid ligands and set as 0%.The data reported
are means ± S.E.M.
3. Results
3.1. Antinociceptive Effect of ACHC-EM2 after Acute Treat-
ments. In the first part of the study, the antinociceptive effect
of the new ligand, ACHC-EM2, was evaluated and compared
to that of its parent peptide, EM2, in tail-flick tests. Rats
were injected icvwith different doses of the peptides between
100 pg and 20𝜇g as indicated in Figure 1. Animals treated
with lower doses of ACHC-EM2 displayed a concentration-
dependent increase (20–50%) in analgesic response com-
pared to base-line values. The acute antinociceptive effect
peaked around 10–15min, followed by a rapid decrease,
which dissipated by 40min following injection (Figure 1).
Higher doses (1 and 20 𝜇g) of ACHC-EM2 displayed around
60% antinociceptive responses which were somewhat higher
than those of the parent peptide, EM2 (45%), which peaked
at an earlier time (10min).
3.2. Analgesic Tolerance Develops to the Antinociceptive Effect
of ACHC-EM2 after Chronic Treatments. In the next set
of experiments, rats were repeatedly injected twice daily
with ACHC-EM2 (20𝜇g, icv) and the antinociceptive effect
was measured 5 and 15min following injection on various
treatment days. It can be seen that the antinociceptive effect
gradually decreased with time compared to day 1, which
became statistically significant by day 5 and ceased by day 10
showing the development of analgesic tolerance (Figure 2).
3.3. Potency and Efficacy of ACHC-EM2 in Activating G-
Proteins In Vitro. ACHC-EM2 was measured in the ligand-
stimulated [35S]GTP𝛾S functional assay in crude rat brain
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Table 1: Changes in DAMGO-stimulated [35S]GTP𝛾S binding induced by in vivo chronic opioid peptide treatments in rat brain subcellular
fractions.
Treatment
𝐸max (% over basal) EC50 (nM)
SPM MI SPM MI
Control Treated Control Treated Control Treated Control Treated
ACHC-EM2 95 ± 5 106 ± 5 85 ± 9 109 ± 2 44 ± 6 80 ± 8∗ 100 ± 18 179 ± 25∗
DAMGO 112 ± 12 130 ± 14 60 ± 3 72 ± 9 87 ± 9 107 ± 14 101 ± 14 86 ± 2
DAMCK 112 ± 12 100 ± 9 60 ± 3 61 ± 17 87 ± 9 126 ± 22 101 ± 14 200 ± 42∗
ACHC-EM2, DAMGO, and DAMCK were chronically administered to rats as described in Methods. Control animals received CSF. Subcellular fractionation
of brain homogenates to obtain synaptic plasma membrane (SPM) and microsomal (MI) fractions was performed. Full concentration curves of DAMGO,
consisting of 5-6 concentrations between 10−8–10−4M, were measured in [35S]GTP𝛾S binding assay. The parameters shown were obtained from nonlinear
regression analysis using Graph Pad Prism 4 considering a sigmoidal dose response curve for DAMGO. Results shown are as % stimulation of [35S]GTP𝛾S
binding over basal values (i.e., binding in the absence of DAMGO). Data are mean ± S.E.M. of 3–6 independent experiments each performed in triplicate.
Significant difference between the appropriate values in control and treated membrane fractions was determined by the Student’s 𝑡-test and set as ∗𝑃 < 0.05.
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Figure 3: Stimulation of [35S]GTP𝛾S binding by opioid peptides
in crude rat brain membranes. Membrane homogenates (≈ 10 𝜇g
of protein) were incubated with increasing concentrations (10−9–
10−4M) of the indicated ligands and [35S]GTP𝛾S (0.05 nM) as
described in Methods except that 30 𝜇MGDP was used. The curves
were fit and drawn by Graph Pad Prism 4 computer program.
Results are shown as % stimulation of [35S]GTP𝛾S binding over
basal values (i.e., binding in the absence of opioid peptides). Each
value represents the mean ± S.E.M. of at least three independent
experiments performed in triplicate. Nonvisible S.E.M. is within the
symbol.
membranes and compared to that of EM2 and the prototypic
full agonist, DAMGO. Full dose-response curves of the three
peptides were assessed between 10−9−10−4Mand efficacy and
potency values were determined (Figure 3). The 𝐸max value
of DAMGO was set as 100% by definition. The efficacy was
significantly lower for both ACHC-EM2 and EM2 with 𝐸max
values of 71.7 ± 1.1 and 52.5 ± 0.8%, respectively. These
data show that both ACHC-EM2 and EM2 behave as partial
agonists in this assay. The potency of the three peptides
in stimulating G-protein activation was very similar, with
log EC
50
value of ACHC-EM2 being 6.37 ± 0.03.
3.4. Changes in G-protein Stimulation due to Chronic Treat-
ments with Mu-Opioid Peptide Agonists. Brains exposed to
repeated agonists treatments leading to analgesic tolerance or
vehicle were simultaneously processed in every experiment.
Control and treated brain homogenates were subjected to
subcellular fractionation to obtain highly purified SPM and
MI membrane fractions. Functional coupling of mu-opioid
receptors to G-proteins was examined by measuring the
ability of DAMGO, added to the membrane fractions in vitro,
to facilitate [35S]GTP𝛾S binding (Table 1). The potencies of
DAMGO were 44 ± 6 nM and 100 ± 18 nM, and efficacies
of 95 ± 5 and 85 ± 9% in control (vehicle administered)
SPM and MI, respectively. Chronic treatment with ACHC-
EM2 resulted in a significant shift of the dose-response curve
of DAMGO to the right; accordingly the EC
50
values of
DAMGO increased to 80 ± 8 nM and 179 ± 25 nM in treated
SPM and MI, respectively. Chronic treatment with DAMCK
also resulted in attenuated G-protein coupling in the MI
fraction. There was a similar tendency in the SPM which,
however, did not reach a statistically significant level. Chronic
DAMGO treatment did not cause any change in [35S]GTP𝛾S
incorporation.The efficacies, reflected in the 𝐸max values, did
not change due to any treatments (Table 1).
3.5. Changes of Receptor Densities due to Chronic Treat-
ments with Mu-Opioid Peptide Agonists. Changes in the
binding parameters of mu-opioid receptors were measured
in [3H]DAMGO homologous displacement experiments
(Table 2). As expected, the 𝐾
𝐷
values were not significantly
changed due to acute or chronic ACHC-EM2 treatments.
Acute injection of a single dose (20𝜇g) of the endomorphin
derivative did not change the 𝐵max values in any fractions.
Notably, chronic treatment with this peptide resulted in a
significant (42%) increase in the density of mu-sites in the
MI fraction (Table 2, Figure 4(a)). On the contrary, chronic
treatments with the full agonist DAMGO resulted in a 22%
decrease in the density of surface mu-sites (Figure 4(b)).
Similar effect was detected with the chloromethyl ketone
derivative of DAMGO, DAMCK, with a concomitant 40%
increase in the MI fractions (Figure 4(c)).
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Figure 4: Changes in receptor density (𝐵max) following chronic exposure of ACHC-EM2 (a) DAMGO (b), and DAMCK (c). SPM (white
columns) and MI (striped columns) fractions were prepared from whole brain. The membrane suspensions (0.3mg protein) were incubated
with 1 nM [3H]DAMGO for 60min at 25∘C in the absence (total binding) or in the presence of 10−10–10−5M of unlabeled DAMGO. Results
are expressed as % change of protein in each fraction. Mean ± S.E.M.; n = 3–6; significance was determined by 𝑡-test; ∗𝑃 < 0.05 compared to
control.
Table 2: Changes in [3H]DAMGO binding induced by ACHC-EM2 treatments in rat brain subcellular fractions.
Treatment
𝐾
𝐷
(nM) 𝐵max (fmol/mg protein)
SPM MI SPM MI
Control Treated Control Treated Control Treated Control Treated
ACHC-EM2 acute 5.0 ± 1.9 3.0 ± 1.1 2.3 ± 0.4 3.6 ± 0.9 298 ± 72 258 ± 45 410 ± 59 311 ± 74
ACHC-EM2 chronic 2.9 ± 1.2 1.3 ± 0.2 4.5 ± 2.4 2.5 ± 0.2 291 ± 82 286 ± 50 333 ± 78 462 ± 54∗
ACHC-EM2was injected either acutely or chronically as described inMethods. Control animals received CSF. Subcellular fractionations of brain homogenates
to obtain synaptic plasma membrane (SPM) and microsomal (MI) membranes followed by [3H]DAMGO binding was performed as outlined in Methods.
Data represent the mean ± S.E.M. of at least three independent experiments performed in duplicate. Statistically significant differences due to either treatments
compared to appropriate control values in each fraction were determined by Student 𝑡-test and set at ∗𝑃 < 0.05.
4. Discussion
In one part of the work, we have described the pharmaco-
logical features of the new endomorphin derivative, ACHC-
EM2, upon its icv administration in the rat tail-flick test.
Acutely, it is slightly more potent than the parent peptide,
EM2, having 60 and 45% maximal antinociceptive effect
values, respectively (Figure 1). These results are consistent
with several investigations in acute pain tests showing that
endomorphins exhibited steady plateau at 40% of maximal
antinociceptive effect [2, 36–38]. We have shown previously
that the prototypic mu-agonist peptide, DAMGO, and its
chloromethyl ketone derivative, DAMCK, display profound
antinociception of about 80% with distinct time-course. The
effect of DAMGOwas longer-lasting, which peaked by about
30min and followed by a rapid dissipation, whereas DAMCK
showed an apparently irreversible antinociception [32]. This
is in accordance with its irreversible binding to mu-sites in in
vitro binding assays. It is to be noted that we have intracere-
broventricularly administrated EM2 and ACHC-EM2, while
the antinociceptive effects were examined by using the
tail-flick test, mostly a spinal reflex. Opioids are involved
in both ascending and descending components of pain
modulation. Given supraspinally, multiple descending pain
control pathways are involved in antinociception induced by
opioid agonists. Interestingly, distinctmechanismsmediating
descending pain controls for antinociception induced by
supraspinally administered EM1 and EM2 were described in
the mouse [39].
It has been revealed that full analgesic tolerance develops
to the antinociceptive effect of 20𝜇g ACHC-EM2 by a 10-
day treatment (icv, twice daily) (Figure 2). For a comparison,
tolerance development was also tested for DAMGO and
DAMCK. Itwas found that behavioral tolerancewas complete
by an 8-day icv injection of 10 𝜇g of the latter two peptides
(twice daily (data not shown)). For further biochemical
studies, the doses of the peptides were designed to maximize
tolerance and were not equieffective as performed with other
ligands [19].
Since the ligand-stimulated [35S]GTP𝛾S functional assay
measures receptor mediated G-protein activation, it may be
a viable tool to detect adaptations associated with tolerance
at the mu-opioid receptor. We have revealed that both EM2
and its new derivative are partial agonists, contrary to the
full agonist DAMGO, in the ligand-stimulated [35S]GTP𝛾S
functional test in crude rat brain membranes (Figure 3). This
is in an excellent agreement with our data in the tail-flick
analgesia test and recent work, which showed that EM2 has
a much lower operational efficacy for G-protein mediated
responses than DAMGO at native mu-opioid receptors in
mature neurons [40]. However, tolerance to [35S]GTP𝛾S
incorporation following chronic opioid peptide treatments
was not detected in all cases, even when full analgesic
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tolerance was manifested. It was found that chronic ACHC-
EM2 treatment decreased the EC
50
of DAMGO by about
2-fold showing attenuated coupling of mu-sites to their
cognate G-proteins in both SPM andMImembranes. Similar
changes were observed upon prolonged DAMCK treatment.
On the contrary, chronic DAMGO injection resulted in no
significant changes in either the potency or in the efficacy of
G-protein signaling (Table 1). The question arises whether a
different picture would have been obtained on ACHC-EM2-
stimulated [35S]GTP𝛾S signaling. Differences in the pattern
of G-protein activation have been reported for agonists at
mu-opioid receptors, including EM-1 versus EM2 and EM-
2 versus DAMGO and morphine [41–43]. In the present
work, we did not attempt to identify the G-protein subtypes
involved in the effect of each ligand. For detecting desen-
sitization, G-protein activation by the full agonist DAMGO
may be a better choice than the partial agonist ACHC-EM2,
whichmay induce either incomplete stimulation of the entire
mu-opioid receptor population or full stimulation of only a
portion of the entire receptor population. Another reason for
testing DAMGO-stimulated [35S]GTP𝛾S binding is that the
present study is part of a comprehensive work using various
mu-opioid ligands of distinct efficacy, chemical nature, and
abuse potential to assess regulatory changes due to analgesic
tolerance, and this set-up was used in our previous studies
[28, 29].
Ligand-specific changes were also detected for receptor
trafficking (Figure 4). While chronic DAMGO and DAMCK
decreased the density of surface mu-receptors, such changes
were not evident by ACHC-EM2. Instead, the density of mu-
sites increased by about 40% in the light membrane fraction
of ACHC-EM2 tolerant brain homogenates compared to that
of vehicle-treatedMI fraction (Figure 4(c), Table 2). Previous
works from other laboratories have revealed region-specific
receptor adaptation in the brain [42, 43]. It is to be considered
whether compounds injected via the icv route are able to
reach the entire population of mu-opioid receptors in the
central nervous system. There are reports suggesting that
the compounds may remain in the vicinity of the ventricles.
On the contrary, icv administration of the opioid antagonist
beta-funaltrexamine was shown to reduce the density of mu-
opioid receptors as measured by in situ autoradiography by
40–50% throughout the brain, with little regional variations
[44]. Since it is not possible to gain sufficient amount of
membrane proteins in subcellular fractions of small tissues,
we have measured mu-opioid receptor density in crude
membranes. [3H]DAMGO binding was downregulated by
about 22% in the hippocampus, upregulated by 33% in the
spinal cord, and did not significantly change in the cortex and
brainstem due to chronic ACHC-EM2 treatments (data not
shown).
Overall, distinct regulatory changes were noted for the
three opioid peptides, albeit all caused full analgesic toler-
ance. This is in accordance with a growing number of data
showing that different opioid ligands can lead to varying
degrees of receptor regulation. The recently discovered phe-
nomenon of “biased agonism” can provide the molecular
basis for the observed ligand-specific effects. It is anticipated
that different agonists stabilize distinct active conformations
of the receptor, thereby inducing distinct downstream signal-
ing [25, 26, 45]. A very recent paper has shown that endomor-
phins seem to be biased toward arrestin recruitment over G-
protein activation contrary to DAMGO [40]. Morphine has
been shown to be biased toward 𝛽-arrestin2 regulation of the
mu-opioid receptors. It was published that knocking-out this
protein enhanced and prolonged morphine antinociception
in the hot-plate test and attenuated tolerance [46]. Although
the precise role of arrestins in the regulation of mu-opioid
receptors in neurons remains to be fully elucidated, it may
explain the observed ligand-specific effects in the present
work and others. Functional selectivity may open up new
directions for designing potent analgesics with less unwanted
side effects.
5. Conclusions
Chronic icv treatment with the partial agonist endomorphin
analog, ACHC-EM2, resulted in the development of analgesic
tolerance in the rat tail-flick test. This was accompanied by
desensitization of the mu-receptors in subcellular fractions
of rat brain. Also, the mu-receptors were upregulated by
about 40% in the light membrane fraction with no detectable
change in surface binding. The prototypic full mu-agonist
peptide, DAMGO, and its chloromethyl ketone derivative,
DAMCK, also induced tolerance, yet the accompanying
molecular changes were different. These results are in accor-
dance with the recently discovered phenomenon, that is, the
so-called “biased agonism” or “functional selectivity”. The
new concept may help to identify new lead molecules, which
can substitute morphine in pain treatment with improved
pharmacological profile.
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